Novartis successfully development formulation for clinical studies and commercial manufacturing of Pluvicto for treatment of Cancer patients. PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have already been treated with other anticancer treatments (androgen receptor pathway inhibition (ARPI) and taxane-based chemotherapy). It is a type of precision cancer treatment combining a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle). After administration into the bloodstream, Pluvicto binds to target cells, including prostate cancer cells that express PSMA, a transmembrane protein. Once bound, energy emissions from the radioisotope damage the target cells and nearby cells disrupting their ability to replicate and/or triggering cell death.

Novartis Pluvicto™ approved by FDA as first targeted radioligand therapy for treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer in 2022. Pluvicto is the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with mCRPC that combines a targeting compound (ligand) with a therapeutic radioisotope (a radioactive particle).

Novartis is reimagining cancer care with radioligand therapy (RLT) for patients with advanced cancers. RLT is a form of precision nuclear medicine that may recognize and treat disease. By harnessing the power of radioactive atoms and applying it to advanced cancers through radioligand therapy, RLTs are able to deliver radiation to target cells anywhere in the body. The goal of the targeted approach is to limit the damage to surrounding tissues.

Pluvicto, novel Radio Ligand Therapy is the latest innovation in manufacturing for drug product to treat cancer patients.